Medicamenteuze prévenue van osteoporose bij gebruik van corticosteroiden

Nederlands Tijdschrift voor Geneeskunde

Volumn 142, Issue 34, 1998, Pages 1904-1908

  Lems, W F ^a  

^a Sector Neuropsychologie V K   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM DERIVATIVE; COLECALCIFEROL; CORTICOSTEROID;

BONE DENSITY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; HUMAN; MALE; MIDDLE AGED; OSTEOPOROSIS; REVIEW;

ADRENAL CORTEX HORMONES; BONE DENSITY; CALCIUM COMPOUNDS; CHOLECALCIFEROL; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS;

EID: 0032558190     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lems WF, Jacobs JWG, Raymakers JA, Bijlsma JWJ. Botontkalking door corticosteroïden. Ned Tijdschr Geneeskd 1992:136: 1595-9-
2. Eastell R. Management of corticosteroid-induced osteoporosis. UK Consensus Group Meeting on Osteoporosis. J Intern Med 1995; 237:439-47
3. Recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996:39: 1791-801.
4. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996:313:344-6.
5. Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis 1995:54:668.
6. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990:112:352-64.
7. Adachi JD, Bensen WJ, Hodsman AB. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 1993:22:375-84.
8. Bijlsma JWJ. Prevention of glucocorticoid induced osteoporosis. Ann Rheum Dis 1997:56:507-9.
9. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995:54:49-52.
10. Lems WF, Jahangier ZN, Raymakers JA, Jacobs JWG, Bijlsma JWJ. Methods to score vertebral deformities in patients with rheumatoid arthritis. Br J Rheumatol 1997:36:220-4.
11. Rüegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol :983;25:6is-20.
12. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced ostopenia in patients with rheumatic diseases. Arthritis Rheum 1985; 28:361-8.
13. LoCascio V, Bonucci E, Imbimbo B, Ballanti P, Adami S, Milani S, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner 1990:8:39-51.
14. Eggelmeijer F, Papapoulos SE, Paassen HC van, Dijkmans BAC, Valkema R, Westedt ML, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996:39:396-402.
15. Boers M, Verhoeven AC, Markusse HM, Laar MAFJ van de, Westhovens R, Denderen JC van, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet I997;35o:309-i8.
16. Ross PD. Osteoporosis. Frequency, consequences and risk factors. Arch Intern Med I9g6;i56:i399-4ii.
17. Lems WF, Gerrits MI, Jacobs JWG, Vugt RM van, Rijn HJM van, Bijlsma JWJ. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996:55:288-93.
18. Laan RFJM, Riel PLCM van, Putte LBA van de, Erning LJThO van, Hof MA van 't, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized controlled study. Ann Intern Med 1993:119:9638.
19. Netelenbos JC, Lips P. Botdichtheidsmeting en de preventie van fracturen: wie komen hiervoor in aanmerking? Ned Tijdschr Geneeskd 1996:140:1061-4.
20. Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitrol and calcitonin. N Engl J Med 1993328:1747-52-
21. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroidinduced osteoporosis. N Engl J Med 1997337:382-7.
22. Bijlsma JWJ, Raymakers JA, Mosch C, Hoekstra A, Derksen RWHM, Baart de la Faille H, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced ostopenia. Clin Exp Rheumatol 1988:6:113-9.
23. Reid 1R, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr i986;44:287-9O.
24. Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol i996;23:995-iooo.
25. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin 03 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med i996;i25:96i-8.
26. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992:7:1063-9.
27. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 199437:1499-505
28. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997336:1769-75.
29. Colditz GA, Hankinson SE, Hunter DJ, Willet WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-93.
30. Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Kaufman JM. Etidronate in the prevention of corticosteroid-induced bone loss: a randomized placebo-controlled prospective study [abstractJ. J Bone Miner Res T 997; 12:626.
31. Saag KG, Emkey R, Schnitzer J, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998339:292-9.
32. Reid 1R, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. Lancet I988;ii:ii44.
33. Adachi JD, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, et al. Intermittent cyclical therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994; 21:1922-6.
34. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994; 33:348-50.
35. Struys A, Snelder AA, Mulder H. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med I995J99:23542.
36. Healey JH, Paget SA, Williams-Russo P, Szatrowski TP, Schneider R, Spiera H, et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int I996;s8:73-8o.
37. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996-456:1173-7.
38. Lems WF, Jacobs JWG, Bijlsma JWJ, Croone A, Haanen HCM, Houben HHML. Effect of sodiumfluoride in prevention of corticosteroid-induced osteoporosis. Osteoporosis Int i997;7:575-82.
39. Lems WF, Jacobs JWG, Bijlsma JWJ, Veen GJM van, Houben HHML, Haanen HCM. Is addition of sodium fluoride to cyclical etidronate beneficial in the treatment of corticosteroid-induced osteoporosis? Ann Rheum Dis 1997:56:357-63.